Background: Trigeminal neuralgia (TN) is a neurological syndrome characterized by paroxysmal, lightning-like, severe pain in the facial area innervated by the trigeminal nerve. Patients who do not respond well to drug treatment can undergo a nerve block, a traditional conservative treatment. Pulsed radiofrequency (PRF) is a nondestructive pain intervention technique. However, its treatment effectiveness for TN has rarely been reported and remains controversial among scholars. A recent single-center preliminary clinical study showed that high-voltage PRF was significantly effective in the treatment of TN. However, whether high-voltage PRF is a viable pain treatment option for TN patients who are unresponsive to drug treatment must still be confirmed with standardized clinical studies by utilizing conservative nerve block treatment as a control.
www.painphysicianjournal.com tigated the efficacy of PRF with standard voltage for TN and the effective rate was only 35% (12) . However, our subsequent study confirmed that among refractory TN patients who were unresponsive to drugs and nerve block, the one-year response rate (69%) with high-voltage PRF treatment was significantly higher than that with standard voltage (19%) (15) . High-voltage PRF would allow a significant number of patients to avoid undergoing other surgical treatments that are associated with greater side effects and risks. However, it remains unclear whether it is a viable therapeutic choice for TN patients in whom pharmacological treatment is ineffective. Thus, standardized clinical studies that utilize nerve blocks as a control are required to provide stronger evidence. Therefore, the aim of this study is to design a multicenter, randomized, double-blind, controlled study to compare the long-term pain relief effectiveness of CT-guided high-voltage PRF treatment and traditional nerve block treatment on Gasserian ganglion for TN patients in whom conservative drug treatment is ineffective. We seek to determine whether high-voltage PRF could be a minimally invasive, safe, effective and durable treatment option for primary TN patients.
OBJECTIVE
This is a prospective, multicenter, randomized, double-blind, controlled clinical study designed to compare the efficacy and safety of high-voltage PRF and nerve block for primary TN patients who have failed to respond to drug treatment and are seeking a better non-surgical treatment option.
SETTING
The study will enroll patients from Beijing Tiantan Hospital, Beijing Friendship Hospital, and Beijing Ditan Hospital, China. All researchers will be trained using the same training protocol. All researchers are required to have clinical experience with both therapies and to have practiced both therapies clinically for over one year before participating in this study.
Approval of the Study Protocol
All procedures in the trial are in accordance with the World Medical Association's "Helsinki Declaration (version 19 October 2013)". The study plan (protocol version 1.0) is approved by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University, China (KY2017-004-01). The study strategy has been registered at ClinicalTrails.Gov (NCT03131466).
T T
rigeminal neuralgia (TN) is characterized by paroxysmal, recurrent, electric shock-like severe pain within the facial region innervated by the trigeminal nerve. The preferred treatment for TN is antiepileptic drug therapy. However, no new breakthroughs have been made in drug treatment for TN in recent years. TN patients who do not respond to drug therapy can choose nerve block treatment with local anesthetic and steroid. Moreover, these patients can elect to undergo a novel, nondestructive treatment known as pulsed radiofrequency (PRF).
The one-year response rate of one-time nerve block treatment for TN is low. Multiple repeated treatments are often needed to achieve a certain clinical effectiveness (1-3). Therefore, traditional nerve block treatment raises several concerns such as puncture operation-associated risks, local anesthetic drugs and steroid-associated side effects. PRF is a new type of neuromodulation technique. The initially proposed PRF parameters are a pulse frequency of 2 Hz, an output voltage of 45 V, an output frequency of 500 kHz, a continuous current action of 20 ms, and an intermission period of 480 ms. Within these parameters, the heat can be dissipated, the temperature during treatment will not exceed 42°C, and the heat will not cause target tissue injury (4-7). The nature of PRF offers attractive clinical prospects. Up to now, the efficacy of PRF in the treatment of TN is not yet unanimously recognized by all researchers. In 2003, Van Zundert et al (8) first reported that PRF treatment in 5 TN patients achieved satisfactory efficacy. In 2015, Nader et al (1) reported a TN patient underwent PRF treatment and achieved 100% pain relief for over 6 months without any side effects. In contrast, a prospective, randomized, controlled study by Erdine et al (9) in 2007 reported no effectiveness of PRF for the treatment of TN. Moreover, Elawamy et al (10) compared the effectiveness of PRF, continuous radiofrequency (CRF) and CRF combined PRF for idiopathic TN and found that PRF achieved the least effective rate. Nowadays, PRF is not yet recommended as a therapeutic method in TN treatment guidelines because of limited data from clinical studies.
As early as 2006, Teixeira and Sluijter (11) first proposed the concept of high voltage PRF with adjusting the output voltage from standardized 45 V to 60 V on patients with discogenic pain and achieved a very significant fall in the numeric rating scale (NRS) scores over the first 3 months. Our previous studies found that the output voltage of PRF for the treatment of TN under computed tomography (CT) guidance is positively correlated with its efficacy (12) (13) (14) . In 2014, we have inves-Investigation of PRF in TN: A Multicenter, Double-blind, RCT Study
Informed Consent
All enrolled TN patients have the right to be informed of the study's objective, experimental procedure, benefits of the study and possible risks. All patients will sign written informed consent. Each patient will be given sufficient time to consider whether to participate in the study. Patients who participate in the study will be freely allowed to obtain more information, withdraw their consent, or discontinue participation without restrictions at any time.
Study Population
One hundred thirty-four patients who meet the inclusion criteria will be enrolled in the study. The patients will be randomly divided into 2 groups. The high-voltage PRF group will undergo 42°C high-voltage PRF treatment, and the nerve block grou p will undergo n erve block treatment with steroid and local anesthesia.
Pr e-Enrollment Evaluation
The pre-enrollment evaluation will determine the demographic and preoperative data of patients, including age (years), gender (male or female), duration of disease (months), pain distribution (V1, V2, V3, V1-2, V2-3, V1-3), pain laterality (left / right), dosage of antiepileptic drugs (milligrams per day), Barrow Neurological Institute (BNI) pain intensity score (Table 1) , and patient satisfaction score (PSS) (9) . The BNI pain intensity score (16) includes 2 elements, the pain intensity element defined into 4 levels: none, occasional, some, and severe while the element of the situation of medication usage classified into no medication, reduced medication, and continued medication use (17) . PSS scores will be used to evaluate patient satisfaction: 0 point indicates unsatisfactory, while 10 points indicate very satisfactory. 
Inclusion Criteria

Subject Eligibility and Identification
After each patient signs the informed consent, the researchers will complete the eligibility checklists according to the items listed on the case report form (CRF). If the patient does not meet any of the inclusion criteria, he or she will not be enrolled in the clinical study, and exclusion will be noted.
Study Interventions
Procedure
Patients will lie in a supine position with their neck slightly extended on the CT scan bed and will be continuously monitored for blood pressure, heart rate, electrocardiogram and pulse oximetry. The negative plate of a PMG-230 Pain Management Generator (Baylis Medical Inc., Montreal, Canada) will be affixed to the patient's supper back, and the puncture treatment and other procedures will be conducted under aseptic conditions. Hartel's anterior approach will be used, and the puncture point will be approximately 3 cm outside the commissure of the mouth on the affected side. Anesthesia will be locally applied, and the 5-mm active tip Table 1 . BNI pain intensity scoring criteria. 
BNI Pain Intensity Score Definition
. CT-guided puncture of the Gasserian ganglion. A) Location image. B) (the horizontal view ) CT scan showing the tip of the trocar entering the foramen ovale.C) (skull base view) 3D CT reconstruction imaging showing that the trocar entering the foramen ovale. D) (interior skull base view) 3D CT reconstruction imaging showing that the trocar entering the foramen ovale.
of the 10-cm long, 21-gauge radiofrequency treatment trocar (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) will be inserted under the guidance of threedimensional reconstruction using a thin-layer (2 mm/ layer) CT scan (SOMATOM SIEMENS Company, Munich, Germany) of the skull base until the tr ocar accurately punctures the foramen ovale (Fig. 1) .
The stylet will be removed, and a radiofrequency electrode (PMK-21-100, Baylis Medical Inc., Montreal, Canada) will be inserted. Electrical stimulation (50 Hz) will be used to determine the sensory threshold. A prickling sensation in the area innervated by trigeminal nerve can be induced by 0.1 -0.3 V covering the painful site. Additionally, 2Hz electrical stimulation will be used Investigation of PRF in TN: A Multicenter, Double-blind, RCT Study to test the motor threshold. 0.1 -0.3 V can induce motion of mandible. The depth and direction of the trocar will be adjusted slightly corresponding to the patient's sensation and movement to ensure the accuracy of the puncture location.
The patients will be randomly divided into a nerve block group and a PRF group. In the nerve block group, a radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360 s sham PRF treatment (20) , after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment trocar. Before the trocar is removed, 0.5 mL of normal saline will be injected (21, 22) . In the PRF group, the pain treatment generator (15, 23, 24) will be set to manual PRF mode, and the upper temperature limit will be set to 42°C.The PRF output voltage will then be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 mL of a mixture of 0.4 mL of normal saline and 1 mL of 1% lidocaine will be injected through the trocar. Before the trocar is removed, 0.5 mL of normal saline will be injected.
Additional Interventions
If the Gasserian ganglion puncture is not successful or the treatment is not completed for other reasons, the patient will be considered a contravention of the project and will be excluded from the study. After treatment, the patient will be observed in the outpatient recovery room for approximately 6 h. The patient will be discharged from the hospital if he/she does not experience any discomfort. After treatment, the patients' doctors will decide whether to continue adjuvant antiepileptic drugs according to their condition, and the drug dosage will be adjusted based on the degree of pain.
Patients can be unblinded upon request or if they experience any emergency conditions. Unblinded patients and patients lost to follow-up will be considered withdrawn from the study. If the researchers determine that the treatment is ineffective or if the patients are not satisfied with the efficacy after one month, the patients can elect to switch to microvascular decompression, radiofrequency thermocoagulation, gamma knife treatment, or another more invasive treatment after unblinding. After one month of treatment, patients whose treatment is defined as effective by the researchers but later experience a relapse of pain can also be unblinded. These patients can then choose to undergo repeated nerve blocks, PRF or other more invasive therapies.
Follow-up
Patients in both groups are required to complete a 1-year follow-up. The follow-up evaluations will include postoperative short-term (postoperative day 1, week 1, week 2, month 1, month 3 and month 6) and long-term (year 1 and year 2) BNI scores, PSS scores, antiepileptic drug dosages (milligrams per day), adverse events (AEs) and information regarding patients with a BNI score of IV and V who switch to other therapies.
Outcomes
Prim ary Outcome
The primary outcome parameter is the 1-year response rate of TN treatment with high-voltage PRF and traditional nerve block. The BNI score will be used to assess pain degree. The degree of pain relief will be evaluated as "excellent" (BNI pain score I-II), "good" (BNI pain score III), or "poor" (BNI pain score IV-V). The response rate will be calculated as [excellent and good pain relief (BNI I -III)]/ [total number of cases] *100%.
Seco ndary Outcomes
The secondary outcome parameters will include the postoperative response rates at day 1, week 1, week 2, month 1, month 3, month 6, and year 2, PSS scores at each follow-up time point with in 2 years, dosage of adjuvant antiepileptic drugs, intraoperative and postoperative AEs, and data regarding patients with a BNI of IV or V who switch to other treatments.
Data Management and Analysis
Sample Size
Previous studies regarding Gasserian ganglion block have reported only cases with satisfactory results without examining the response rate. The 1-year response rate of 1-time treatment for TN using maxillary and mandibular blocks administered via a modified coronoid approach was 25% (3). Based on clinical experience, the response rate of Gasserian ganglion block under CT guidance is expected to be 40% higher than the response rate of maxillary and mandibular blocks. Previous studies have reported that the one-year response rate of high-voltage PRF on Gasserian ganglion under CT guidance to treat TN was 69% (15) . With 134 www.painphysicianjournal.com patients in total (67 in each arm), we have 90% power to test the difference of 40% response rate in treated group and 69% response rate in the control group, with an  = 0.05 and a drop-out rate of 10%.
Statistical Methods
All statistical analyses were performed with SAS 9.4. The Shapiro-Wilk test will be used to test whether all data follow a normal distribution. Data with a normal distribution will be expressed as the mean ± standard deviation. Data without a normal distribution will be expressed as the median and interquartile range.
A differential test will be used to compare the efficacy outcome indexes between the PRF group and the nerve block group. The outcome measures of the 2 groups will be compared at all the time points. Chi-square test and Fisher's exact test will be used for categorical variables. Student's t test will be used for continuous variables with a normal distribution, and the Mann-Whitney U test will be used for data without a normal distribution. In addition, the outcome measures in each group at all postoperative time points will be compared with the preoperative data in the same group. Categorical data will be analyzed using a paired chi-square test, while measurement data will be analyzed using paired t test or signed-rank test. Descriptive analyses will be used for all randomized and treated patients to evaluate safety indicators. A P-value of ≤ 0.05 will be considered statistically significant.
Intent-to-treat (ITT) and Per-Protocol (PP) Analyses
Intent-to-treat analysis and per-protocol analysis will be performed to analyze data. For patients who drop out from the study, the initial data or the last follow-up data will be utilized in accordance with specific conditions. Before unblinding the intervention measures, the responsible biometrician will determine whether the patient will be allocated to the PP analysis or ITT analysis.
Randomization and Allocation Concealment
The present study will enroll a total of 134 patients, and the patients will be randomized to 1 of the 2 study groups, each group with 67 patients (1:1 randomization). The randomization will be separately performed by the researchers at the 3 centers. After patients have been confirmed to meet the basic inclusion criteria, they will be randomly divided into 1 of the 2 research groups using a randomization sequence generated by SAS software.
Each research center will appoint a research nurse who will oversee the allocation. A random data table will be prepared beforehand. A sealed opaque randomized envelope will be given in the order of the consecutively enrolled patients. After the intraoperative puncture reaches Gass erian ganglion, the sealed envelope, which will contain the concealed randomized treatment protocol, will be opened by the research nurse, and the patient will be assigned to undergo the corresponding treatment. The research nurse will also be responsible for preparing the respective drugs to be used for intraoperative injection in the 2 groups.
Blinding
The patients and the pain doctors responsible for conducting the intervention treatment will be blinded to the group assignment. The sound of the radiofrequency generator will be turned off during the treatment. The research nurse will oversee operating the radiofrequency generator to perform PRF treatment or sham treatment based on the patient's grouping. After the treatment and before the trocar is removed, the pain doctor will slowly inject drugs prepared by the research nurse. Other than the research nurse, neither the personnel in the treatment room nor the patient will know the treatment assignment. The trained pain doctors will conduct blind evaluations at all postoperative time points.
Safety Assessments
During intraoperative and all postoperative followup time points (postoperative day 1, week 1, week 2, month 1, month 3, month 6 year 1 and year 2), the details of any AEs or adverse device effects reported by the subject will be documented in the CRF. The record will include the nature, start time, duration time, severity, relationship with the intervention treatment and prognosis of such events. The incidence of AEs will be reported by the subject and evaluated by the follow-up doctor. Intraoperative and postoperative AEs include vomiting, bradycardia, facial hematoma, transient diplopia, dysesthesia, masseter weakness, corneal anesthesia, keratitis and other incidences ( Table 2) . At each follow-up time point, the follow-up doctor will evaluate the degree of patients' AEs as "mild," "moderate," or "severe."
All AEs, regardless of their relationship with the study or severity, will first be treated by the researchers in a timely and appropriate manner until they are satisfactorily resolved. The AEs will be documented in the subject's CRF, and the study monitor will be informed Investigation of PRF in TN: A Multicenter, Double-blind, RCT Study of the AEs. The severity and treatment of the AEs and their relationship with the study device/procedure will be reported. Severe AEs or adverse device effects that occur during the study, such as fatal or life-threatening events, must be immediately reported to the Institutional Review Board (IRB).
RESULTS
Patient Flow
An illustration of the sequence of events during participation is shown in Table 3 .
Recruitment
Recruitment will begin in April 2017 and will end in December 2018.We have completed interventions on 2 patients.
Baseline Data
Baseline demographics and clinical features will be documented including age (years), gender (male or female), duration of disease (months), pain distribution (V1, V2, V3, V1-2, V2-3, V1-3), pain laterality (left / right), dose of adjuvant antiepileptic drugs (milligrams per day), BNI score at baseline, and PSS. Significant differences will be assessed between the groups. Baseline data will be presented as shown in Table 4 .
Data Analysis
The duration of this study is proposed to be from April 2017 to December 2019 and will include the selection of 134 patients (67 patients in each group). The SAS 9.4 statistical analysis system will be used to analyze the follow-up data, and the obtained results will be presented as shown in Table 5 .
Efficacy
BNI, PSS, and the dosage of adjuvant antiepileptic drugs at postoperative day 1, week 1, week 2, month 1, month 3, month 6, year 1 and year 2 will be illustrated for the two groups, and significant differences will be compared between the 2 groups. In addition, the response rates of both groups will be calculated and compared.
Safety
The incidence of the AEs assoc iated with the device and/ or the procedure during the operation and throughout the entire postoperative follow-up period of the 2 groups will be compared. All study-related AEs will be monitored, and details about AEs including the nature, severity, duration, treatment, and relationship to the study procedure will be reported. The occurrence of all AEs will be identified by the study principal investigators.
DISCUSSION
According to the TN treatment guidelines published by the American Academy of Neurology (AAN) and the European Federation of Neurological Societies (EFNS) (25) , patients who have a poor response to carbamazepine or oxcarbazepine treatment are recommended to undergo surgical treatment. However, some patients do not want to receive surgical treatment or have contraindications for surgical treatment.
Surgical treatment includes nerve-damaging minimally invasive interventional therapies such as percutaneous retrogasserian glycerol injection, radiofrequency thermocoagulation, balloon decompression, and stereotactic radiosurgery (SRS). Moreover, it also includes neurosurgical microvascular decompression (MVD) (19, 26) . Unfortunately, evidence regarding the efficacy of interventional procedures is limited, and all inter- Investigation of PRF in TN: A Multicenter, Double-blind, RCT Study Adverse event rate (% ventions have their own shortcomings. For example, after percutaneous radiofrequency thermocoagulation is performed, the region innervated by the trigeminal nerve may present hypesthesia, masseter muscle weakness and other discomfortable symptoms (27) , which significantly influence patient quality of life. The treatment of TN with SRS has a slower onset, and the therapeutic effect is correlated with dose. Although increasing the dose can improve efficacy, it simultaneously increases the risk of facial numbness (28) . MVD is one of the most effective therapeutic methods for TN patients (29) (30) (31) (32) . However, it will be ineffective without neurovascular compression (NVC). Moreover, MVD is not suitable for patients with advanced age, complications or weakness (33) . Therefore, despite the existence of a variety of treatment options, the long-term efficacy of TN remains unsatisfactory.
With the acceleration of aging of the global population, the number of TN patients is increasing, particularly including the number of elderly TN patients. Thus, it is urgent to explore minimally invasive, safe, effective, and persistent non-surgical treatment options such as intranasal spray, subcutaneous injections, nerve blocks, botulinum toxin injection and PRF. Future studies should focus on improving the efficacy of non-surgical treatment options and providing scientific and medical evidence to support innovative non-surgical technologies as choices before surgery and for patients who are reluctant to undergo surgical treatment.
In recent years, PRF has been increasingly used to treat clinical chronic pain disorders as a neuromodulation treatment, including discogenic pain (11, 34, 35) , postherpetic neuralgia (36), chronic lumbosacral radicular pain (37) (38) (39) , and phantom limb pain (40) (41) (42) in whom pharmacological treatment and nerve block are ineffective achieve higher success rates after PRF treatment (8, 43) . Clinical studies providing stronger evidence are required to further clarify the value of PRF for the treatment of TN. Previous studies have reported that nerve block treatment of TN often requires multiple punctures and injection of local anesthetic drugs and steroids (1,3) . While, one-time PRF treatment may provide a longer period of pain relief in TN patients (8) . However, there is currently no report that has compared the efficacy of nerve block and PRF in TN patients in whom drug treatment is ineffective. Among the growing number of studies on improving the efficacy of PRF technology for TN treatment (12, 13, 15, 43, 44) , high-voltage PRF is a particularly promising option for the treatment of refractory TN (15, 44) . By comparing the differences in efficacy between high-voltage PRF and nerve block treatment for TN, the present study can provide TN patients who have poor responses to drug treatment with a more effective treatment option with fewer side effects. The results of this study may help to optimize treatment guidelines for TN.
Previous reports have revealed that puncture of Gasserian ganglion was often performed under the guidance of C-arm imaging (9), which is not as intuitive as the guidance of reconstructed three-dimensional CT (12) . Serious c omplications including death hematomas could happen in the procedure of foramen ovale puncturing under the guidance of fluoroscopy (45, 46) . However, patients in both groups in this study will undergo puncture under CT guidance, which will significantly improve the success rate of the puncture and avoid the effect of inaccurate puncture positioning on the results. Bhatjiwale et al reported that the use of the straight RF needle on a patient with ophthalmic division (V1) medically uncontrolled neuralgia obtained satisfactory efficacy with no obvious complications (47) . Our previous studies also demonstrated that the punctures of Gasserian ganglion with the sharp trocar under the guidance of reconstructed 3-dimensional CT were relatively safe without reported complications (12, 13, 15) .
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There is no doubt that the curved blunt needle with an injectable side port may cause less tissue injury during the procedure and it deserves further investigations when blunt needles are commercially available in our country. Although the prognosis indicators of this study are subjective, our use of a randomized, double-blind, controlled design in which both the patients and follow-up doctors are blinded to the treatment allocation will prevent bias. Therefore, the present trial results will offer valuable scientific evidence.
The results of this study are expected to be obtained in 2019, and scientific reports will be published thereafter.
Study Limitations
The present study examines the effectiveness and safety of only 1 year after treatment. However, longer follow-up would provide more significant results. Consistent with similar studies, the present study examines only the degree of pain relief, satisfaction, side effects and other subjective indicators but lacks objective evaluation methods. Electrophysiological examination may provide further information regarding changes in neurological function, which is worth studying in the future. In 2010, Tanaka et al (48) found that increasing the treatment duration of PRF from 120 to 360 seconds showed a significant antiallodynic effect without nerve injury in rats. Recently, PRF treatment was applied for 360 seconds in several clinical studies (49, 50) . In this study, we also selected to investigate the treatment duration of 360 seconds with PRF. In a prospective double blind randomized study, van Kleef et al (6) evaluated the efficacy of radiofrequency lesion at 67°C and the results showed a 67°C radiofrequency lesion could effectively alleviated cervicobrachial pain. Heavner et al (51) found that PRF at 60°C did not cause egg white coagulation in vitro, while above 60°C, PRF produced thermocoagulation similar to CRF (51). Ali Eissa et al reported that the combination of PRF at 45°C for 12 minutes followed by CRF at 60°C for 2 minutes and 65°C for 2 minutes could achieve excellent pain relief and reduced consumption of analgesics for idiopathic TN patients 12 months after the procedure in a retrospective study (49) . In 2017, Elawamy et al (10) compared the effect for idiopathic TN after CRF, PRF, and combined CRF and PRF treatment of the Gasserian ganglion and demonstrated that the best efficacy were observed in the CRF and PRF group, that is, the PRF for 10 minutes at 42°C followed by CRF for 270 seconds at 60°C, and with no complications for 2 year follow-up. Recently, it seems that the PRF combined with 60°C CRF treatment may become a novel technique for the trigeminal neuralgia patients but the clinical studies include small numbers of patients which deserves further investigation. However, the effects of the waveform, treatment duration, pulse width, frequency and other parameters on the efficacy of PRF still need to be studied. We aim to investigate the effectiveness and safety of high-voltage PRF to treat patients with primary trigeminal neuralgia under CT guidance which may restrict access clinically. The punctures under the more common used C-arm imaging guidance deserve to be evaluated in the future. Furthermore, the cost-effectiveness of nerve block and PRF, which is an important issue in clinical practice, is also worth evaluating.
CONCLUSION
This is the first multicenter, randomized, doubleblind, controlled study to compare the effectiveness and safety of PRF and nerve block for the treatment of TN patients who have poor responses to drug treatment. The value of PRF for the clinical treatment of TN needs to be confirmed by conducting evidence-based medical studies and other advanced studies.
